Strategic development of product-specific non-clinical programmes and design of non-clinical safety packages in alignment with current regulatory expectations in all phases of drug development. Contribution to the due diligence process for new opportunities; expert evaluation of non-clinical safety packages, gap analysis according to international guidelines, scientific and regulatory writing (IND, IB, IMPD, MAA/NDA etc.).